PremiumCompany AnnouncementsAbivax Reports First Quarter 2025 Financial Results with Increased R&D Costs ABVX Earnings this Week: How Will it Perform? Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity PremiumThe FlyAbivax management to meet with BTIG Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones Abivax Reports 2024 Financial Results, Eyes Clinical Milestones PremiumPre-EarningsABVX Upcoming Earnings Report: What to Expect? Abivax assumed with an Equal Weight at Morgan Stanley Buy Rating for Abivax SA Driven by Promising Obefazimod Data and Market Potential 
